Literature DB >> 21925187

Effects of estrogen in preventing neuronal insulin resistance in hippocampus of obese rats are different between genders.

Wasana Pratchayasakul1, Nipon Chattipakorn, Siriporn C Chattipakorn.   

Abstract

AIM: The effects of estrogen on the prevention of impaired insulin-induced long-term depression in the hippocampus and neuronal insulin signaling caused by high-fat diet (HF) were studied in male and female rats. MAIN
METHODS: Both male and female rats were fed with a normal diet (ND; 19.7% energy from fat) or a high-fat diet (HF; 59.3% energy from fat) for 12 weeks. Then, rats were divided into four subgroups: ND, ND+E, HF and HF+E. The subgroups with+E were given 50 μg/kg estrogen subcutaneously once a day for 30 days. At the end of the experimental period, blood and brain samples were collected to determine the peripheral insulin resistance and neuronal insulin resistance, respectively. KEY
FINDINGS: Both male and female rats fed with HF developed peripheral insulin resistance as indicated by increased body weight, visceral fat, plasma insulin and HOMA index. Estrogen administration decreased those parameters, indicating improved peripheral insulin sensitivity, in both male and female HF rats. HF diet consumption also caused impaired insulin-induced long-term depression in hippocampus and impaired neuronal insulin receptor function and signaling, indicating neuronal insulin resistance, in both male and female rats. Estrogen treatment could attenuate these neuronal impairments only in HF female rats. SIGNIFICANCE: The activation of the estrogen pathway could preserve insulin sensitivity in the peripheral tissue in both male and female rats. In neuronal tissue, however, the benefit of estrogen could be found only in female rats.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925187     DOI: 10.1016/j.lfs.2011.08.011

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Aging induced by D-galactose aggravates cardiac dysfunction via exacerbating mitochondrial dysfunction in obese insulin-resistant rats.

Authors:  Cherry Bo-Htay; Thazin Shwe; Louis Higgins; Siripong Palee; Krekwit Shinlapawittayatorn; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Geroscience       Date:  2019-11-25       Impact factor: 7.713

2.  Obese-insulin resistance accelerates and aggravates cardiometabolic disorders and cardiac mitochondrial dysfunction in estrogen-deprived female rats.

Authors:  Sivaporn Sivasinprasasn; Piangkwan Sa-Nguanmoo; Wasana Pratchayasakul; Sirinart Kumfu; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Age (Dordr)       Date:  2015-03-20

3.  Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Natticha Sumneang; Chayodom Maneechote; Busarin Arunsak; Titikorn Chunchai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

4.  Estrogen and insulin transport through the blood-brain barrier.

Authors:  Aaron A May; Nicholas D Bedel; Ling Shen; Stephen C Woods; Min Liu
Journal:  Physiol Behav       Date:  2016-05-13

5.  Hyperbaric oxygen therapy effectively alleviates D-galactose-induced-age-related cardiac dysfunction via attenuating mitochondrial dysfunction in pre-diabetic rats.

Authors:  Cherry Bo-Htay; Thazin Shwe; Thidarat Jaiwongkam; Sasiwan Kerdphoo; Wasana Pratchayasakul; Thienchai Pattarasakulchai; Krekwit Shinlapawittayatorn; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Aging (Albany NY)       Date:  2021-04-16       Impact factor: 5.682

Review 6.  Links Between Obesity-Induced Brain Insulin Resistance, Brain Mitochondrial Dysfunction, and Dementia.

Authors:  Jirapas Sripetchwandee; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-31       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.